×

INC Research's Michael Gibertini and Alan Ong Named to Annual PharmaVOICE 100

RALEIGH, N.C., Aug. 3, 2015 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced Michael Gibertini, PhD, President, Clinical Development, and Alan Ong, Executive Vice President, Asia/Pacific, have been named to the annual PharmaVOICE list of the 100 most inspiring people in the life sciences industry. Known as one of the top clinical development experts in the central nervous system (CNS) research field, Dr. Gibertini was recognized for his work in advancing trial design through innovative approaches and leading the growth of the Company's CNS unit. Mr. Ong was praised for his pivotal leadership role in building the Company's Asia/Pacific capabilities and in skillfully navigating the complex markets, cultures, regulations and drug development environments throughout the region.

"We are so delighted to see Michael and Alan recognized for their contributions to the life sciences industry and for the inspiration and motivation they provide to our customers and employees around the world," said Jamie Macdonald, Chief Executive Officer, INC Research. "Driven by patient need, both Michael and Alan possess a unique ability to look beyond the business strategy alone to find solutions that improve the patient experience. Michael's therapeutic expertise and visionary leadership inspire those around him to strive to do what is best for the patients that are served by the therapies we help develop. Alan is a strong advocate for the Asia/Pacific region, working to expand awareness of the world-class research capabilities available across Asia, while ensuring that the global and local aspects of clinical development work together."

Dr. Gibertini joined INC Research in 2005 and has more than 30 years of experience in the pharmaceutical and CRO industries, as well as in academic, private practice and hospital settings. As President of Clinical Development, he is responsible for driving the growth of INC's therapeutic offerings globally, enhancing the Company's focus on therapeutic foresight and continuing to drive a differentiated business model through thought leadership and delivery excellence in clinical development. During his tenure, he has guided INC Research's CNS business to record results and is well regarded as an expert and leader in CNS clinical trials methodology.

Mr. Ong joined INC Research in 2014 and leads the Company's clinical development efforts in Asia/Pacific overseeing 12 countries, including Australia and Japan. Before joining INC Research, he built multiple businesses in the region for another multinational CRO, improving revenue, increasing quality and reducing turnover. Since joining INC Research, he has committed himself to improving the Company's Asia/Pacific operations and empowering and developing a strong regional leadership team to meet and exceed the ambitious vision and goals for the region. Over the past year, INC has increased headcount in this important region by approximately 25 percent. He is based in Singapore.

Dr. Gibertini and Mr. Ong were selected from a group of nominations submitted by industry peers. A panel of PharmaVOICE editors evaluated the submissions based on nominees' ability to inspire, motivate and influence corporate leadership, research and development, technology, creativity, marketing and strategy. The two are featured in the July/August 2015 issue of PharmaVOICE.

About INC Research

INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked "Top CRO to Work With" among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, N.C., with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com.

CONTACT: Investors: Ronnie Speight, +1 919 745 2745 Media: Lori Dorer, +1 513 345 1685

Source:INC Research

More From Press Releases